<DOC>
	<DOCNO>NCT01633177</DOCNO>
	<brief_summary>The VITamin D OmegA-3 TriaL ( VITAL ; NCT 01169259 ) ongoing randomize clinical trial 25,875 U.S. men woman investigate whether take daily dietary supplement vitamin D3 ( 2000 IU ) omega-3 fatty acid ( Omacor® fish oil , 1 gram ) reduce risk develop cancer , heart disease , stroke people prior history illness . This ancillary study conduct among nondiabetic participant VITAL examine whether vitamin D fish oil prevent type 2 diabetes . Findings propose study conduct within VITAL trial clarify whether vitamin D omega-3 fatty acid supplementation reduces risk type 2 diabetes thus inform public health clinical guideline diabetes prevention .</brief_summary>
	<brief_title>Study Vitamin D Omega-3 Supplementation Preventing Diabetes</brief_title>
	<detailed_description>Emerging evidence suggest favorable effect vitamin D marine omega-3 fatty acid glucose homeostasis . Optimal vitamin D intake essential insulin secretion action , omega-3 fatty acid may reduce diabetes risk result favorable effect insulin sensitivity , endothelial function , chronic inflammation , metabolic abnormality . Although metabolic effect vitamin D omega-3 fatty acid show considerable promise primary prevention type 2 diabetes ( T2D ) , complete , ongoing , plan randomize clinical trial vitamin D omega-3 supplement include T2D primary outcome general population . We thus propose utilize NIH-funded randomize trial ( 1 U01 CA138962 ) test hypothesis vitamin D omega-3 supplementation reduce risk T2D . We assess whether extent vitamin D omega-3 supplementation improve insulin sensitivity pancreatic beta-cell function subsample trial cohort . The VITamin D OmegA-3 TriaL ( VITAL ) randomize , double-blind , placebo-controlled trial specifically design evaluate benefit risk vitamin D3 ( 2,000 IU/day ) marine omega-3 fatty acid ( eicosapentaenoic acid [ EPA ] + docosahexaenoic acid [ DHA ] , 1g/day ) supplement primary prevention cancer cardiovascular disease ( CVD ) . The VITAL trial aim enroll 20,000 men woman ( age ≥50 ≥55 year , respectively ) . The planned treatment duration 5 year 1.5-year recruitment period . This diabetes ancillary study aim implement inexpensive efficient strategy validate self-reported incident T2D case entire trial population collect pre- post-intervention measure glucose , insulin , hemoglobin A1c ( HbA1c ) subset participant . Two method diabetes case validation propose . First , plan collect detailed information diagnostic glucose test anti-diabetic medication use medical record and/or supplementary questionnaire complete participant 's physician . Second , complement diabetes ascertainment process , also plan retrieve additional data diabetes diagnose hypoglycemic medication link participant Centers Medicare Medicaid Services ( CMS ) database . In addition evaluate whether study intervention impact onset clinical diabetes , propose collect pre- post-intervention measure glucose , insulin , HbA1c subset participant reliably ass whether vitamin D omega-3 supplementation alters insulin glucose homeostasis . We plan recruit 1,000 participant without prior clinical diabetes Clinical Translational Science Center ( CTSC ) site Brigham Women 's Hospital . A standard 2-hour oral glucose tolerance test ( OGTT ) HbA1c measurement perform CTSC visit baseline 2-year post-randomization . Primary Aims : 1 . To test whether vitamin D3 and/or EPA+DHA supplementation reduces risk T2D among initially non-diabetic participant VITAL trial . 2 . To test whether vitamin D3 and/or EPA+DHA supplementation improve insulin sensitivity beta-cell function subset 1,000 non-diabetic participant receive OGTT baseline 2-year post-randomization . Secondary Aims : 1 . To test whether vitamin D3 and/or EPA+DHA supplementation lower HbA1c , fast glucose insulin , well surrogate index insulin sensitivity beta-cell function determine homeostasis model assessment ( HOMA-IR HOMA- % B , respectively ) substudy . 2 . To test whether vitamin D3 EPA+DHA supplementation exert synergistic additive effect risk T2D among initially non-diabetic participant VITAL trial . 3 . To test whether vitamin D3 EPA+DHA supplementation exert synergistic additive effect insulin sensitivity beta-cell function assess OGTT substudy . For main effect estimate , explore whether effect vitamin D3 EPA+DHA supplementation varies ( 1 ) age , ( 2 ) sex , ( 3 ) baseline intakes nutrient , ( 4 ) baseline level 25 ( OH ) D ( vitamin D3 ) , ( 5 ) race/skin pigmentation ( vitamin D3 ) , ( 6 ) geographic region ( vitamin D3 ) , ( 7 ) BMI ( vitamin D3 ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Participants VITAL ( NCT01169259 ) history diabetes mellitus baseline eligible participate ancillary study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>vitamin D</keyword>
	<keyword>omega-3 fatty acid</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Oral glucose tolerance test ( OGTT )</keyword>
	<keyword>Insulin sensitivity</keyword>
	<keyword>Beta-cell function</keyword>
</DOC>